

Resource Summary Report

Generated by [dkNET](#) on Apr 22, 2025

PRECISESADS

RRID:SCR_003882

Type: Tool

Proper Citation

PRECISESADS (RRID:SCR_003882)

Resource Information

URL: <http://www.precisesads.eu/>

Proper Citation: PRECISESADS (RRID:SCR_003882)

Description: A project that will study 2,500 people with various systemic autoimmune diseases (SADs), gathering data on the molecular causes of their disease as well as their clinical symptoms, enabling them to pave the way for a new classification of these diseases. The goal is to use OMICs and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Results will be shared to deliver a new molecular taxonomy of systemic autoimmune diseases. In order to achieve this, PRECISEADS is informing on a regular basis on the project implementation and results, and involving stakeholders from Europe in its activities in order to broaden the project impact and increase opportunities for cooperation.

Abbreviations: PRECISESADS

Synonyms: PRECISESADS - Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases

Resource Type: organization

Keywords: biomarker, diagnostic, basic research, clinical, genomics, transcriptomics, epigenomics, flow cytometry, cellular separations, pre-clinical model, proteomics, metabolomics, serology, tissue, taxonomy, imaging, biosample, sample collection, biobanking, blood, urine

Funding: Innovative Medicines Initiative ; EFPIA

Resource Name: PRECISESADS

Resource ID: SCR_003882

Alternate IDs: nlx_158209

Record Creation Time: 20220129T080221+0000

Record Last Update: 20250420T014156+0000

Ratings and Alerts

No rating or validation information has been found for PRECISESADS.

No alerts have been found for PRECISESADS.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Castellini-Pérez O, et al. (2024) Molecular subtypes explain lupus epigenomic heterogeneity unveiling new regulatory genetic risk variants. *NPJ genomic medicine*, 9(1), 38.

Ortega-Ferreira C, et al. (2023) Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis. *Nature communications*, 14(1), 5291.

Lindblom J, et al. (2023) Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. *Frontiers in immunology*, 14, 1257085.

Foulquier N, et al. (2022) Machine Learning for the Identification of a Common Signature for Anti-SSA/Ro 60 Antibody Expression Across Autoimmune Diseases. *Arthritis & rheumatology (Hoboken, N.J.)*, 74(10), 1706.

Barturen G, et al. (2022) Whole blood DNA methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection. *Nature communications*, 13(1), 4597.

Soret P, et al. (2021) A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. *Nature communications*, 12(1), 3523.

Marziale A, et al. (2020) Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases. *Journal of autoimmunity*, 115, 102524.

Le Lann L, et al. (2020) Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. *Scientific reports*, 10(1), 11567.

Thiagarajan D, et al. (2020) IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. *Scientific reports*, 10(1), 11010.

Fernández-Ochoa Á, et al. (2020) A Case Report of Switching from Specific Vendor-Based to R-Based Pipelines for Untargeted LC-MS Metabolomics. *Metabolites*, 10(1).

Carnero-Montoro E, et al. (2019) Epigenome-Wide Comparative Study Reveals Key Differences Between Mixed Connective Tissue Disease and Related Systemic Autoimmune Diseases. *Frontiers in immunology*, 10, 1880.

Cossu M, et al. (2018) Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective. *Clinical reviews in allergy & immunology*, 55(3), 312.

Schuhmacher A, et al. (2018) Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? *Journal of translational medicine*, 16(1), 119.